BRIDGEWATER, N.J., June 29, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate in and moderate a scientific panel discussion at the 2nd Annual JAK Inhibitors Drug Development Digital Event, to take place virtually June 29-July 1, 2021. Event Details: Day:   Wednesday, June 30, 2021 Time:  2:40pm Eastern Time Panel:  Past, Present & Future Combinational Opportunities with JAKi Topics to be addressed on the panel include the current dearth of JAK inhibitors in certain disease profiles and speculation on the use of combinational approaches and…

BRIDGEWATER, N.J., May 06, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. “Our sales organization continues to drive utilization of AMZEEQ and ZILXI, with prescriptions for both products gaining momentum,” said David Domzalski, Chief Executive Officer of VYNE Therapeutics. “During the first quarter, we unveiled our newest candidate FMX114, a combination topical gel product candidate for the treatment of mild-to-moderate atopic dermatitis. We plan to take FMX114 into a Phase 2a study in the third quarter, with top-line…

BRIDGEWATER, N.J., April 28, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the first quarter ended March 31, 2021, on Thursday, May 6, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

BRIDGEWATER, N.J., April 28, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the first quarter ended March 31, 2021, on Thursday, May 6, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details: Thursday, May 6th @ 8:30am Eastern Time Toll Free:  800-909-4985 International: 312-281-1211 Conference ID: 21993618 Webcast: http://public.viavid.com/index.php?id=144542 A replay of the call will be archived on the Company’s website at www.vynetherapeutics.com…

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference. Presentation details can be found below. Barclays Global Healthcare Conference Day: Tuesday, March 9, 2021 Time: 8:00am Eastern Time Format: Fireside chat Webcast Link: https://kvgo.com/2021-global-healthcare-conference/vyne-therapeutics-2021     H.C. Wainwright Global Life Sciences Conference Day & Time: On demand, beginning 7:00am Eastern Time, Tuesday, March 9, 2021 Format: Fireside chat Webcast Link: https://journey.ct.events/view/7534c623-91e5-4fa6-9d64-6dbed8781b9a About VYNE Therapeutics Inc.VYNE’s mission is…

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference. Presentation details can be found below. Barclays Global Healthcare Conference Day: Tuesday, March 9, 2021 Time: 8:00am Eastern Time Format: Fireside chat Webcast Link: https://kvgo.com/2021-global-healthcare-conference/vyne-therapeutics-2021     H.C. Wainwright Global Life Sciences Conference Day & Time: On demand, beginning 7:00am Eastern Time, Tuesday, March 9, 2021 Format: Fireside chat Webcast Link: https://journey.ct.events/view/7534c623-91e5-4fa6-9d64-6dbed8781b9a About VYNE Therapeutics Inc.VYNE’s mission is…